IPCA Laboratories Q2 FY26 Financial Performance Review

IPCA Laboratories Ltd. has announced a robust financial performance for the second quarter ending September 30, 2025. The company reported a significant 23.1% year-on-year (YoY) increase in consolidated net profit, which reached ₹282.6 crore compared to ₹229.4 crore in the corresponding quarter of the previous fiscal year. This strong profitability was underpinned by healthy operational improvements and steady revenue growth. Key Financial Highlights (Q2 FY26 vs. Q2 FY25) Consolidated Revenue: Grew 8.6% YoY to ₹2,556.5 crore, supported by balanced growth across key markets. EBITDA: Increased substantially by 23.5% YoY to ₹545.5 crore. EBITDA Margin: Expanded significantly by 258 basis points (bps) to 21.33%, up from 18.75% in the prior-year period, highlighting improved operating efficiency. Consolidated Net Total Income: Stood at ₹2,584.36 crore, reflecting a 9% growth from the previous year. Segment Performance & Market Drivers The company's growth was broad-based, with positive contributions from both domestic and international operations: Indian Formulations: This segment registered a solid 8% YoY growth, achieving revenues of ₹1,018.9 crore. Exports Income: The export business also demonstrated resilience, growing 7% YoY to ₹813.65 crore. Market Reaction Following the results announcement, the shares of IPCA Laboratories ended the trading session at ₹1,294.50 on the NSE, down 3.46%.